APCCC 2024 | Addressing unmet needs in treating aggressive variant prostate cancer

Andrew Armstrong, MD, Duke University, Durham, NC, discusses strategies for treating aggressive variant prostate cancer, including the use of platinum doublet chemotherapy and the significance of biomarkers like DLL3, CXCR2, and GPC3. Prof. Armstrong highlights ongoing clinical trials such as CHAMP (NCT04180104) and Synergy 201 (NCT04016116), as well as emphasizes the importance of biopsies and NGS testing for tailored treatments. This interview took place at the 2024 Advanced Prostate Cancer Consensus Conference (APCCC) in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.